On June 4, 2026, the U.S. Supreme Court ruled unanimously (9–0) in favor of Hikma Pharmaceuticals USA Inc., reversing a lower court decision and delivering a monumental victory to the generic drug industry regarding the use of "skinny labels."

A "skinny label" is an FDA-approved label for a generic drug that omits patented uses of the brand-name drug, allowing the generic to be marketed only for non-patented indications under the Hatch-Waxman Act.

The high court held that Amarin Pharma, Inc. failed to plausibly allege that Hikma actively induced patent infringement. The decision firmly establishes that generic drug manufacturers cannot be held liable for patent inducement based on neutral, standard marketing statements or public information, even if healthcare providers might ultimately interpret those statements as an instruction to prescribe the generic drug for patented, off-label uses.

SCOTUS ruled 9-0 in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., reversing a lower court decision and sending the case back for further proceedings, marking a rare moment of full agreement on a court often portrayed as ideologically divided. Jackson, a Biden appointee, has been one of the court’s most frequent dissenters, making her authorship of a unanimous opinion all the more notable.

The decision set up the legal standard for when claims that generic drugmakers encouraged patent infringement can proceed when they market medicines with “skinny labels,” which exclude patented uses—a shift that may affect how lower-cost drugs are brought to market.

That ruling goes beyond the courtroom as this case could affect how quickly cheaper generic drugs enter the market and how companies describe their products’ risks. Legal standards like the one clarified in the ruling can determine both drug prices and the volume of lawsuits tied to widely used medications. Generic drugs account for the vast majority of prescriptions in the United States, and drugmakers warned that a decision favoring Amarin could have discouraged cheaper alternatives, potentially driving up prices.

The case now returns to the lower courts, where judges will apply the Supreme Court’s clarified legal framework to determine whether Amarin’s claims can proceed under the proper standard.

Background of the Case

Amarin Pharma markets icosapent ethyl under the brand name Vascepa. In 2012, the FDA approved Vascepa for treating severe hypertriglyceridemia (the SH indication), which affects patients with blood triglyceride levels of at least 500 mg/dL. The drug was first approved for treating severe hypertriglyceridemia (the "SH indication", which is off-patent). It was later approved to reduce cardiovascular risk the "CV indication", which Amarin holds method-of-use patents for.

In 2019, following additional research and clinical trials, the FDA approved Vascepa for a second use: reducing cardiovascular risk in patients with triglyceride levels of at least 150 mg/dL (the cardiovascular or CV indication). Amarin listed two patents covering the CV indication in the FDA’s Orange Book.

In 2016, Hikma Pharmaceuticals submitted an Abbreviated New Drug Application seeking approval for a generic version of icosapent ethyl. When the CV indication was approved in 2019, Hikma filed a “section viii statement” seeking FDA approval only for the SH indication by “carving out” the patented CV indication from its label—creating a “skinny label.” 

The FDA approved Hikma’s ANDA in May 2020. Throughout 2020, Hikma issued press releases referring to its product as the “generic version” or “generic equivalent” of Vascepa, describing Vascepa as indicated “in part” for the SH indication, and citing Vascepa sales figures (over $1 billion annually) that were attributable primarily to the CV indication. 

In November 2020, Amarin sued Hikma for induced infringement of its CV indication patents. The U.S. District Court for the District of Delaware granted Hikma’s motion to dismiss. The U.S. Court of Appeals for the Federal Circuit reversed, finding that Amarin’s allegations—based on Hikma’s skinny label combined with its press releases and marketing materials—plausibly stated a claim for induced infringement.

The Main Question

1. When a generic drug manufacturer excludes a patented use from its label, can it still be liable for inducing infringement if it calls its product a “generic version” of the brand-name drug and cites publicly available information about the brand-name drug’s sales?

2. Can a patent infringement complaint survive dismissal if it does not allege that the defendant made any statement specifically instructing or encouraging the patented use?